Compare ERII & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERII | BIOA |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | 62 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.9M | 681.9M |
| IPO Year | 2008 | N/A |
| Metric | ERII | BIOA |
|---|---|---|
| Price | $8.11 | $17.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $17.07 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 1.3M | 388.7K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $134,987,000.00 | N/A |
| Revenue This Year | N/A | $720.93 |
| Revenue Next Year | $20.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.14 | $3.93 |
| 52 Week High | $18.31 | $24.00 |
| Indicator | ERII | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 33.47 | 49.16 |
| Support Level | N/A | $15.49 |
| Resistance Level | $11.58 | $19.01 |
| Average True Range (ATR) | 0.42 | 1.17 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 1.61 | 51.56 |
Energy Recovery Inc designs and manufactures energy-saving technologies. The firm uses its proprietary pressure exchanger technology to help customers in multiple industries improve their operations and lower their emissions. Using its proprietary technology, it offers energy recovery devices, including pressure exchangers, pumps, and turbochargers, mainly used for seawater desalination and wastewater treatment. Additionally, the company is involved in the development of emerging technologies, such as the PX G1300 used in industrial and commercial refrigeration applications. The firm's reportable operating segments are: Water, which generates maximum revenue, and Emerging Technologies. Geographically, it generates maximum revenue from the Middle East, and the rest from other markets.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.